Here are the 10-Q quarterly reports from BriaCell Therapeutics Corp. Warrant (BCTXZ) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BCTXZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCTXZ filings page.
BriaCell Therapeutics Corp. reported a larger net loss as it accelerated cancer immunotherapy development. For the nine months ended April 30, 2026, the company lost $22.8 million, up from $18.4 million a year earlier, driven mainly by higher research, development, and clinical trial expenses of $18.7 million versus $14.2 million.
Cash, cash equivalents, and short-term investments totaled $22.8 million, with cash of $6.9 million and positive working capital of $21.8 million. However, a cumulative deficit of $134.3 million and operating cash outflows of $22.7 million over nine months led management to state that substantial doubt exists about BriaCell’s ability to continue as a going concern without additional financing.
Clinically, BriaCell advanced its Bria-IMT™ pivotal Phase 3 study in metastatic breast cancer under FDA Fast Track Designation, reporting extended survival and favorable safety signals, and broadened its pipeline with Bria-OTS™, Bria-OTS+™, and Bria-PROS+™ including new FDA clearance to begin a Phase 1/2a study for Bria-BRES+™.